Sunday, January 11, 2015

Seeking Alpha: AngioDynamics Still Looking For Inflection

What AngioDynamics (NASDAQ:ANGO) does is not easy. This small med-tech company competes with huge players like Bard (NYSE:BCR) and Covidien (NYSE:COV) (as well as Teleflex (NYSE:TFX)) in markets that are not growing all that fast and where a large sales/marketing effort and the ability to bundle can make a significant difference in closing sales. AngioDynamics hasn't always helped their own cause either, with issues in manufacturing, quality control (including a recent FDA Warning Letter), and financial reporting.

The company is making progress, though, and seems to be nearing a point where margins and profits could grow disproportionately to incremental revenue growth. The company has also managed to add several products to its portfolio that offer real benefits to health care professionals (and savings to the facilities) and their patients. I'm not so crazy about the valuation here, but if management could push revenue growth above 5% the shares could still do rather well.

Follow this link for more:
AngioDynamics Still Looking For Inflection

No comments: